CTLA4 and melanoma: For example, a study of patients with melanoma brain metastasis showed that concurrent immunotherapy with anti-PD-L1 and anti-CTLA-4 showed improved response rates if immunotherapy was given within a time frame of 4 weeks after radiation compared to treatments that were more than 4 weeks apart (122).